礼来公司高管近日指出，复合药物在市场上依然广泛流通。与此同时，该公司正持续推进法律维权行动，并积极敦促美国食品药品监督管理局（FDA）采取相应监管措施。
礼来公司高管近日指出，复合药物在市场上依然广泛流通。与此同时，该公司正持续推进法律维权行动，并积极敦促美国食品药品监督管理局（FDA）采取相应监管措施。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.